NeoGenomics (NEO) Set to Announce Quarterly Earnings on Tuesday

NeoGenomics (NASDAQ:NEO) is scheduled to release its earnings data before the market opens on Tuesday, April 30th. Analysts expect NeoGenomics to post earnings of ($0.03) per share for the quarter. NeoGenomics has set its FY 2024 guidance at EPS.Individual that wish to listen to the company’s earnings conference call can do so using this link.

NeoGenomics (NASDAQ:NEO) last released its quarterly earnings results on Tuesday, February 20th. The medical research company reported ($0.02) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.05. NeoGenomics had a negative return on equity of 4.13% and a negative net margin of 14.87%. The firm had revenue of $155.55 million during the quarter, compared to the consensus estimate of $152.90 million. On average, analysts expect NeoGenomics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

NeoGenomics Price Performance

NASDAQ NEO opened at $13.42 on Tuesday. The firm’s 50 day moving average is $15.08 and its 200-day moving average is $15.89. The company has a quick ratio of 5.95, a current ratio of 6.20 and a debt-to-equity ratio of 0.57. The company has a market capitalization of $1.71 billion, a PE ratio of -19.17 and a beta of 1.10. NeoGenomics has a 12-month low of $11.03 and a 12-month high of $21.22.

Insider Activity

In other NeoGenomics news, General Counsel Alicia C. Olivo sold 2,587 shares of the firm’s stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $14.96, for a total transaction of $38,701.52. Following the completion of the sale, the general counsel now directly owns 34,866 shares in the company, valued at $521,595.36. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 1.30% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on NEO shares. BTIG Research cut their price target on shares of NeoGenomics from $25.00 to $21.00 and set a “buy” rating on the stock in a research report on Friday, December 29th. Piper Sandler raised their price target on NeoGenomics from $18.00 to $20.00 and gave the company an “overweight” rating in a research note on Monday, February 26th. The Goldman Sachs Group upped their price objective on NeoGenomics from $17.00 to $19.00 and gave the stock a “buy” rating in a research note on Thursday, February 22nd. Needham & Company LLC raised their target price on shares of NeoGenomics from $21.00 to $24.00 and gave the company a “buy” rating in a research note on Wednesday, February 21st. Finally, TD Cowen dropped their price target on shares of NeoGenomics from $22.00 to $19.00 and set an “outperform” rating on the stock in a research report on Friday, December 29th. Three investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $19.50.

NeoGenomics Company Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.